Project with participation of HC of USP and Santa Casa de SP investigates impacts of medicinal cannabis in 2,500 patients

Among the historic corridors of the Hospital das Clínicas of USP and the Santa Casa de Misericórdia de São Paulo, two of the most traditional care and research centers in the country, a project is born that aims to expand the scientific understanding of medicinal cannabis in Brazil. Cannect has launched the largest study in Latin America on the impacts of cannabis on human health, gathering real data from 2,500 patients followed between 2022 and 2025. The proposal is to transform daily clinical experience into structured evidence, with the potential for national and international impact.

Medicinal cannabis: research with 2,500 patients at HC of USP and Santa Casa

Coordinated by the medical director, Rafael Pessoa, with the participation of researcher Renato Anghinah, linked to HC of USP and Santa Casa, the study has an umbrella format, was approved by the Research Ethics Committee (CEP) and already has about 40 structured subprojects.

"We are facing a historic opportunity to understand, with solid scientific basis, what we have already observed in our daily practice with our patients: medicinal cannabis can bring concrete benefits in different clinical conditions. With this study, Brazil positions itself at the forefront of knowledge production on the subject," says the medical director of Cannect.

Real-world study expands scientific evidence on cannabis in Brazil

With a methodology based on real-world studies, the research aims to describe clinical profiles, evaluate the effectiveness of different formulations, including different proportions of THC and CBD, monitor adverse events in prolonged use, and measure impacts on quality of life.

According to the company, the results should support both medical practice and the formulation of public policies, helping to reduce the evidence gap in real treatment scenarios.

With information from the press office.